公开(公告)号：US20180289720A1

公开(公告)日：2018-10-11

申请号：US15938001

申请日：2018-03-28

Applicant: AMGEN INC.

Inventor： Paul E. Harrington ,  Kate Ashton ,  Sean P. Brown ,  Matthew R. Kaller ,  Todd J. Kohn ,  Brian Alan Lanman ,  Kexue Li ,  Yunxiao Li ,  Jonathan D. Low ,  Ana Elena Minatti ,  Alexander J. Pickrell ,  Markian M. Stec ,  Joshua Taygerly

IPC: A61K31/553 ,  A61P35/00

CPC classification number: A61K31/553 ,  A61P35/00 ,  A61P35/02 ,  C07D498/08

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US11306107B2

公开(公告)日：2022-04-19

申请号：US16078152

申请日：2017-02-24

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  David Karl Bedke ,  Michael R. Degraffenreid ,  Jiasheng Fu ,  Zhihong Li ,  Felix Gonzalez Lopez De Turiso ,  Ana Gonzalez Buenrostro ,  Michael W. Gribble, Jr. ,  Michael G. Johnson ,  Todd J. Kohn ,  Kexue Li ,  Yunxiao Li ,  Mike Elias Lizarzaburu ,  Yosup Rew ,  Joshua Taygerly ,  Yingcai Wang ,  Xuelei Yan ,  Ming Yu ,  Jiang Zhu ,  Manuel Zancanella ,  Xian Yun Jiao ,  Liusheng Zhu ,  Xianghong Wang ,  Julio C. Medina ,  Jason A. Duquette ,  Jonathan B. Houze ,  Marc Vimolratana ,  Mario G. Cardozo ,  Alan C. Cheng

IPC: C07D513/10 ,  C07D513/20 ,  C07D515/10

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US11274105B2

公开(公告)日：2022-03-15

申请号：US16977527

申请日：2019-03-04

Applicant: AMGEN INC.

Inventor： Gwenaella Rescourio ,  Ana Gonzalez Buenrostro ,  Sean P. Brown ,  Mike Lizarzaburu ,  Julio Medina ,  Salman Yojiro Jabri ,  Daqing Sun ,  Scott Preston Simonovich ,  Xuelei Yan ,  Yihong Li ,  Yosup Rew

IPC: C07D498/22 ,  C07D498/10 ,  C07D498/20 ,  C07D519/00 ,  A61K31/635 ,  A61K31/7068 ,  A61K38/07

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US10300075B2

公开(公告)日：2019-05-28

申请号：US15938001

申请日：2018-03-28

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  Kexue Li ,  Yunxiao Li ,  Markian M. Stec

IPC: A61K31/553 ,  C07D498/08 ,  A61P35/00 ,  A61P35/02

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US20190201412A1

公开(公告)日：2019-07-04

申请号：US16297904

申请日：2019-03-11

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  Kexue Li ,  Yunxiao Li ,  Markian M. Stec

IPC: A61K31/553 ,  A61P35/02 ,  C07D498/08 ,  A61P35/00

CPC classification number: A61K31/553 ,  A61P35/00 ,  A61P35/02 ,  C07D498/08

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US10100063B2

公开(公告)日：2018-10-16

申请号：US15376456

申请日：2016-12-12

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  Yunxiao Li ,  Mike Elias Lizarzaburu ,  Brian S. Lucas ,  Nick A. Paras ,  Joshua Taygerly ,  Marc Vimolratana ,  Xianghong Wang ,  Ming Yu ,  Manuel Zancanella ,  Liusheng Zhu ,  Ana Gonzalez Buenrostro ,  Zhihong Li

IPC: C07D513/10 ,  C07D513/08

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US11364248B2

公开(公告)日：2022-06-21

申请号：US16638503

申请日：2018-08-17

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  Kexue Li ,  Yunxiao Li ,  Anthony B. Reed ,  Brian Alan Lanman

IPC: A61K31/553 ,  A61K31/496 ,  A61K31/7068 ,  A61K38/07 ,  C07D513/10

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US11279712B2

公开(公告)日：2022-03-22

申请号：US16642441

申请日：2018-08-27

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  Yunxiao Li ,  Paul E. Harrington ,  Brian Alan Lanman ,  Jonathan D. Low ,  Ana Elena Minatti ,  Vu Van Ma ,  Kexue Li

IPC: C07D513/04 ,  C07D513/08 ,  C07D519/00 ,  A61P35/00 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/7068

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US11224601B1

公开(公告)日：2022-01-18

申请号：US17029249

申请日：2020-09-23

Applicant: AMGEN INC.

Inventor： Paul E. Harrington ,  Kate Ashton ,  Sean P. Brown ,  Matthew R. Kaller ,  Todd J. Kohn ,  Brian Alan Lanman ,  Kexue Li ,  Yunxiao Li ,  Jonathan D. Low ,  Ana Elena Minatti ,  Alexander J. Pickrell ,  Markian M. Stec ,  Joshua Taygerly

IPC: A61K31/553 ,  A61P35/02 ,  A61P35/00 ,  C07D498/08

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US10821115B2

公开(公告)日：2020-11-03

申请号：US16783269

申请日：2020-02-06

Applicant: AMGEN INC.

Inventor： Paul E. Harrington ,  Kate Ashton ,  Sean P. Brown ,  Matthew R. Kaller ,  Todd J. Kohn ,  Brian Alan Lanman ,  Kexue Li ,  Yunxiao Li ,  Jonathan D. Low ,  Ana Elena Minatti ,  Alexander J. Pickrell ,  Markian M. Stec ,  Joshua Taygerly

IPC: A61K31/553 ,  A61P35/02 ,  A61P35/00 ,  C07D498/08

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.